- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02436876
Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites
Phase 2a Randomized, Single-Blind, Placebo-Controlled, 12-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Bone Sites
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Postoperative orthopaedic infections, particularly antibiotic-resistant infections, present a serious clinical challenge to surgeons and other treating physicians. These infections frequently involve implanted foreign materials (stabilizing orthopaedic hardware), making infection of these sites much more likely than if foreign materials were not involved. MBN-101 has broad spectrum antimicrobial activity against orthopaedic wound pathogens.
This is a randomized, single-blind, placebo-controlled, multi-center study to assess the safety and tolerability of escalating doses of MBN-101 to treat orthopaedic infections during revision surgery, (a) with or without orthopaedic hardware, and (b) with or without removal and replacement of orthopaedic hardware.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- Orthopedic Trauma Institute, University of California San Francisco
-
San Francisco, California, United States, 94143
- UCSF - Parnassus
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
- LifeBridge Health, Inc.
-
-
Ohio
-
Columbus, Ohio, United States, 443215
- OhioHealth Research Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas - Health Science Center & Medical School at Houston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- To be eligible for this study, each of the following criteria must be satisfied with a "YES" answer (unless not applicable):
Patients who:
- have had operative fracture fixation of the upper extremity (AO/OTA class 15, 11-13, 21-23), lower extremity (AO/OTA class 31-34, 41 44, 81, 82) or pelvis (61, 62), or have undergone arthrodesis, and have subsequently been diagnosed with an apparent fracture site infection or are diagnosed with chronic or acute-on-chronic osteomyelitis of the long bone extremities (including residual amputated limbs)
- have at least one of the following:
- require surgical debridement of infected soft tissue and/or bone, with or without removal and/or placement/replacement of hardware
- male or female between the ages of 18 and 75 at the time the ICF is reviewed and signed
- patients receiving or anticipated to receive systemic antibiotic therapy as per institution's standard of care
- patients requiring postoperative hospitalization for at least 48 hours after revision surgery
- have read and signed the Informed Consent Form (ICF) after the nature of the study has been fully explained
- be willing and able to provide authorization for use and disclosure of personal health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA)
Exclusion Criteria:
To be eligible for this study, each of the following criteria must be satisfied with a "NO" answer (unless not applicable):
- Patients who are no longer hardware dependent or are definitively treated for their infection by hardware removal without replacement
- Patients with multiple, non-contiguous sites of infection
- Pathologic fracture (not including osteoporosis)
- Patient requires immunosuppressive therapy (Topical or inhaled corticosteroids are permitted)
- Serum creatinine, ALT, AST or Alkaline Phosphatase >2.0 times the upper limit of the normal range of the local testing laboratory
- Absolute neutrophil count <1000
- Patients without definitive soft-tissue coverage over the surgical site at time of study product administration
- Any condition that has required treatment with any other bismuth containing compound within the last 2 weeks (i.e., Kaopectate or Pepto Bismol)
- Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months
- Individuals undergoing surgical treatment for more than one infected site
- Patients who are pregnant, lactating, or female patients who have a positive serum hCG (human Chorionic Gonadotropin) as determined by laboratory testing
- Immunocompromised due to illness or organ transplant
- History of chronic or recurrent infections (≥ 3 infections at the same site within 12 months)
- History of any type of cancer (excluding non-melanomatous localized skin cancer or completely excised and cured carcinoma-in-situ of uterine cervix)
- Poorly controlled diabetes mellitus
- History of medical noncompliance
- Other medical conditions which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results.
- Current incarceration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Single, intra-wound local administration of MBN-101; dosage = 0.5 µg/cm2; randomized 3:1 with placebo
|
MBN-101 is a locally administered, anti-infective drug product
Other Names:
The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
Other Names:
|
Experimental: Cohort 2
Single, intra-wound local administration of MBN-101; dosage = 1.5 µg/cm2; randomized 3:1 with placebo
|
MBN-101 is a locally administered, anti-infective drug product
Other Names:
The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
Other Names:
|
Experimental: Cohort 3
Single, intra-wound local administration of MBN-101; dosage = 5.0 µg/cm2; randomized 3:1 with placebo
|
MBN-101 is a locally administered, anti-infective drug product
Other Names:
The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events
Time Frame: 12 weeks
|
This study evaluates the safety and tolerability of single escalating doses of locally administered MBN-101 or placebo, as adjunct to standard of care antimicrobial and surgical therapy.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Treatment Failures
Time Frame: 12 weeks
|
Treatment failure is defined as clinical course requiring additional infection-related interventions including rehospitalization, additional surgery, or additional courses of systemic antibiotics.
|
12 weeks
|
Treatment Failure in Subjects With Antibiotic-resistant Infections
Time Frame: Up to 12weeks
|
Treatment failure in subjects with baseline infections resistant to one or more antibiotics based on Central Laboratory Microbiological data
|
Up to 12weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Brett Baker, MSc, DC, Microbion Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MBN-101-201
- W81XWH-12-2-0100 (Other Grant/Funding Number: CDMRP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Infection
-
NovartisNovartis VaccinesCompletedBacterial Infection | Streptococcal Infection | Gram-positive Bacterial InfectionBelgium, Canada
-
Kirby InstituteNot yet recruitingInvasive Fungal Infections | Infection, Bacterial | Infection, Fungal | Injection Site Infection | Infection, Soft Tissue | Invasive Bacterial Infection
-
Centre Hospitalier Universitaire de BesanconUnknownAntibiotic Resistant Infection | Resistant Infection | Beta Lactam Resistant Bacterial Infection | Bacterial Resistance
-
Assistance Publique Hopitaux De MarseilleUnknown
-
University of DuhokNot yet recruiting
-
Melinta Therapeutics, Inc.Department of Health and Human ServicesCompletedBacterial InfectionUnited States, Bulgaria
-
University of OxfordCompletedPleural Infection | Pleural Infection BacterialUnited Kingdom
-
Jena University HospitalTerminatedSevere Bacterial InfectionBrazil, Colombia, Germany, Turkey
-
PfizerAllerganTerminatedGram-negative Bacterial InfectionUnited States, Hungary, Slovakia, Taiwan, India, Estonia, Greece, Italy
-
PfizerCompletedGram-negative Bacterial InfectionAustralia
Clinical Trials on MBN-101
-
Microbion CorporationCompletedDiabetic Foot InfectionUnited States
-
Microbion CorporationCUBRC, MTEC, and US NavyActive, not recruitingDiabetic Foot | Diabetic Foot InfectionUnited States
-
TR TherapeuticsCompleted
-
Abalonex, LLCNot yet recruitingTraumatic Brain Injury | Cerebral Edema
-
Benjamin IzarTerminatedLeiomyosarcoma | LiposarcomaUnited States
-
Flame BiosciencesCompletedHealthy SubjectsUnited States
-
Alaunos TherapeuticsCompleted
-
Alaunos TherapeuticsCompletedLymphoma | Multiple Myeloma | Acute Leukemia | Chronic Myeloproliferative Disease | Chronic Lymphoproliferative Disease | Poor-risk Myelodysplasia (MDS)United States
-
Brigham and Women's HospitalRecruiting
-
Alaunos TherapeuticsCompleted